- Home
- WWR vs MRNS Comparison
WWR vs MRNS Comparison
Compare WWR & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- MRNS
- Stock Information
- Founded
- WWR 1977
- MRNS 2003
- Country
- WWR United States
- MRNS United States
- Employees
- WWR N/A
- MRNS N/A
- Industry
- WWR Metal Mining
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- MRNS Health Care
- Exchange
- WWR Nasdaq
- MRNS Nasdaq
- Market Cap
- WWR 36.9M
- MRNS 29.9M
- IPO Year
- WWR N/A
- MRNS 2014
- Fundamental
- Price
- WWR $0.89
- MRNS $0.55
- Analyst Decision
- WWR
- MRNS Buy
- Analyst Count
- WWR 0
- MRNS 12
- Target Price
- WWR N/A
- MRNS $4.28
- AVG Volume (30 Days)
- WWR 908.7K
- MRNS 1.7M
- Earning Date
- WWR 03-18-2025
- MRNS 03-04-2025
- Dividend Yield
- WWR N/A
- MRNS N/A
- EPS Growth
- WWR N/A
- MRNS N/A
- EPS
- WWR N/A
- MRNS N/A
- Revenue
- WWR N/A
- MRNS $31,466,000.00
- Revenue This Year
- WWR N/A
- MRNS $14.97
- Revenue Next Year
- WWR N/A
- MRNS $57.65
- P/E Ratio
- WWR N/A
- MRNS N/A
- Revenue Growth
- WWR N/A
- MRNS 1.63
- 52 Week Low
- WWR $0.40
- MRNS $0.22
- 52 Week High
- WWR $1.32
- MRNS $10.50
- Technical
- Relative Strength Index (RSI)
- WWR 56.05
- MRNS 70.23
- Support Level
- WWR $0.85
- MRNS $0.54
- Resistance Level
- WWR $1.32
- MRNS $0.55
- Average True Range (ATR)
- WWR 0.11
- MRNS 0.01
- MACD
- WWR -0.00
- MRNS -0.00
- Stochastic Oscillator
- WWR 30.37
- MRNS 99.41
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.